Precipio (PRPO) Q3 2026 earnings review
Precipio grows its diagnostic kit sales, but operating profit shrinks
Precipio, a maker of cancer diagnostic kits and operator of a pathology lab, grew its smaller product business while its main testing service slowed. Total sales rose 8% from a year ago to $7.3 million as diagnostic kit revenue climbed 40% to $1.0 million, building on last quarter's gain. Chief executive Ilan Danieli highlighted positive cash generation as ending cash passed $3.5 million, but operating profit excluding stock pay and unusual items slipped from a year ago.
| Revenue | $7.3M +8% from a year ago |
|---|---|
| Diagnostic product sales | $1.0M +40% from a year ago |
| Operating profit, excluding one-offs | $0.4M $0.5M a year ago (-20%) |
| Forward outlook | None given no numerical targets issued |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because sustained momentum in diagnostic kits was offset by lower operating margins and a slower pathology lab. Holding product sales at $1.0 million eased fears that last quarter's jump was just a delayed shipment. One caution: operating profit before non-cash charges fell 20% from a year ago despite record sales, and the release does not show how much of the $0.6 million operating cash flow came from one-time pandemic tax credits.
The question now is whether rising product sales can lift profit margins and generate cash once pandemic tax credits run out. Either outside laboratories are adopting the company's blood-cancer tests fast enough to cover new sales-team costs, or rising lab expenses and one-off tax refunds are masking weak underlying cash flow. The third-quarter 10-Q footnotes on tax refunds and division margins will settle it.
🐂 Bull Case
Product Sales Held Last Quarter's Gains
Precipio runs an in-house cancer laboratory that serves as the "clinical development and validation platform for our proprietary diagnostic products", chief executive Ilan Danieli said. It then sells those testing kits and chemical reagents to outside laboratories. Last quarter's jump in kit sales included a delayed customer order from March, which left doubts about whether demand would hold.
The diagnostics maker cleared that bar in the third quarter. Product revenue rose 40% from a year ago to $1.0 million, up from $0.9 million in the second quarter by our math (an 11.1% quarterly gain). That pushed products to 13.7% of total revenue, up from 10.3% a year earlier by our math, proving the spring jump was not just a calendar quirk.
What to watch: the product revenue table and management's call commentary on newly active distributor accounts. A fourth-quarter reading above $1.0 million would show that new distributor reps are converting their customer pipelines into recurring reagent orders.
Operations Added Half a Million to Cash
Danieli said the cancer-testing group wants to "accelerate commercialization of our existing product portfolio" without issuing new stock to pay for it. Operations brought in $0.6 million of cash during the third quarter, or 8.2% of revenue by our math, after generating $0.7 million in the second quarter.
Total cash rose by $0.5 million during the quarter to pass $3.5 million, up more than 52% from $2.3 million a year ago by our math. That leaves about $0.1 million of cash used outside daily operations by our math, giving the New Haven business a wider cushion to fund its sales team.
What to watch: Note 12 in the third-quarter 10-Q filing for any pandemic Employee Retention Credit tax refunds received during the period. Positive operating cash flow after stripping out any one-time tax refund would confirm the business funds itself.
Positives this quarter didn't test
Two standing growth drivers from earlier quarters received no specific numbers in the third-quarter earnings release.
- Distributor customer activations: management previously hired commercial leads and trained reps at Thermo Fisher, McKesson, Medline and Cardinal; the shareholder call will show how many of the 25-plus qualified prospects started ordering.
- Rapid AML one-day blood-cancer test: positioned last quarter as the centrepiece of marketing collaborations and clinical studies; the 10-Q and call remarks will show whether outside laboratories have finished validating the test.
🐻 Bear Case
Pathology Growth Slowed Against Tougher Comparisons
Pathology services, where Precipio diagnoses patient samples in its own clinical lab, bring in 86.3% of company sales by our math. Danieli said this division provides a financial foundation for the company, and its revenue grew more than 20% from a year ago in the first half of 2026.
That pace cooled as the laboratory lapped a much larger year-ago revenue base. Pathology sales rose 5% from a year ago to $6.3 million, and grew 3.3% from the second quarter's $6.1 million by our math. Because pathology dominates the business, its slowdown pulled total revenue growth down to 8% from 22% last quarter.
What to watch: the pathology case volume and revenue-per-case breakdown in the 10-Q filing. A second straight quarterly drop in patient cases after the 5% dip in the second quarter would show the lab is hitting capacity or demand limits.
Operating Profit Shrank Despite Record Sales
"In the third quarter we continued to strengthen our financial position, delivering record revenue while maintaining positive Adjusted EBITDA and generating cash from operations," Danieli said. Adjusted EBITDA is operating profit before interest, taxes, depreciation, intangibles amortization, stock-based pay and unusual items.
While that profit measure stayed positive at $0.4 million, it fell 20% from $0.5 million a year ago even though quarterly sales grew by $0.5 million. By our math, the Adjusted EBITDA margin slipped 1.9 percentage points from a year ago, from 7.4% of revenue down to 5.5%, and lost 0.2 points from the second quarter.
- Revenue: $7.3 million, up $0.5 million (+8%) from a year ago
- Operating profit before non-cash and unusual items (Adjusted EBITDA): $0.4 million, down $0.1 million (-20%) from a year ago
- Non-cash intangibles amortization and stock-based pay: $0.3 million combined, down from $0.5 million a year ago
Because the company strips out depreciation, amortization and stock awards to calculate Adjusted EBITDA, the drop means cash operating costs — the cost of running the lab and selling products, or overhead — rose faster than revenue. The release does not include a full income statement, so the exact expense line that expanded is not yet visible.
What to watch: the cost of sales and operating expense lines in the Form 10-Q income statement. If lab testing costs took a larger share of revenue while higher-margin product sales grew 40%, pathology pricing is under pressure.
Risks this quarter didn't answer
Five standing balance-sheet, cash-quality and legal risks cannot be checked in the summary release and await the Form 10-Q filing.
- One-off tax refunds in cash flow: in the second quarter, $0.4 million of the $0.7 million operating cash flow came from Employee Retention Credit receipts, with about $0.3 million of credits still remaining entering the third quarter.
- Going-concern warning: the second-quarter 10-Q retained formal substantial-doubt language about the company's ability to continue operating without outside funding.
- Customer concentration: a single buyer, Customer A, accounted for 30% of net sales and 37% of unpaid customer bills in the second quarter.
- Reimbursement and bad-debt risk: Medicare represented about 38% of second-quarter sales, and commercial insurers remained largely out-of-network.
- Data-security lawsuit: a consolidated class-action complaint over the December 2025 data incident carried no financial reserve as of June.
💲 Other KPIs
Bottom-line profit under standard accounting reached breakeven at $0.0 million, improving from a $0.1 million loss a year ago and a $0.2 million loss in the second quarter. Lower non-cash charges for stock awards and intangible assets offset the dip in cash operating profit.
Employee stock-option expense fell to $0.1 million, or 1.4% of revenue by our math, down from $0.2 million (2.9% of revenue) a year ago and $0.8 million in the second quarter. That drop reduced dilution pressure and helped lift standard net income to breakeven.
Non-cash charges for writing down intangible assets held steady from the second quarter at $0.2 million, down from $0.3 million a year ago. As a share of sales, the expense fell 1.7 percentage points from a year ago to 2.7% by our math.
❓ Key Questions
Did tax refunds boost third-quarter operating cash flow?
Precipio received $0.4 million of pandemic Employee Retention Credit refunds in the second quarter and had about $0.3 million left to collect. Investors need to know how much of the third quarter's $0.6 million operating cash flow came from daily operations versus tax credits.
Which cash expense line pushed Adjusted EBITDA down 20%?
Revenue rose by $0.5 million from a year ago and high-margin kit sales grew 40%, yet Adjusted EBITDA fell from $0.5 million to $0.4 million. Management has not yet disclosed whether laboratory testing costs, new sales hires, or legal fees caused the squeeze.
What were pathology case volumes and average revenue per case?
Pathology case counts fell 5% from the first quarter to the second quarter, and third-quarter pathology revenue rose 3.3% sequentially. Disclosing the third-quarter case count will show whether patient test volumes rebounded or if price mix carried the revenue gain.
How many distributor pipeline accounts began ordering in the quarter?
After adding roughly 10 distributor sales reps and more than 25 qualified lab prospects in the second quarter, chief executive Ilan Danieli expected accounts to turn active in the second half. Quantifying active accounts and product gross margin would show how fast the pipeline converts.
Why does the company still refrain from issuing numerical targets?
With revenue reaching $7.3 million and cash passing $3.5 million, the cancer-diagnostics provider still gives no quarterly or annual revenue or profit ranges. Publishing formal targets would let investors test management's claim of accelerated future growth.